Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 11, 2026

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
10:48

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

[Second primitive malignant neoplasm after radiotherapy].

J Doyen1, A Courdi, J-P Gérard

  • 1Service d'Oncologie-Radiothérapie, Cyclotron Biomédical, Centre Antoine-Lacassagne, 227 Avenue de la Lanterne, 06200 Nice, France.

Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|July 6, 2010
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to Letter to the Editor: 'A phase III randomised trial on the addition of a contact x-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 years results of the OPERA trial' by J. Meyer, T. Koessler.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

'Folfirinox' chemotherapy combined with contact x-ray brachytherapy 50kVp and 'CAP50' chemoradiotherapy aiming at organ preservation for selected intermediate distal-middle cT2-T3 rectal cancers: A feasibility study.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2024
Same author

2023 A new French revolution: Organ preservation for rectal cancer.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2024
Same author

Patients' needs in proton therapy: A survey among ten European facilities.

Clinical and translational radiation oncology·2023
Same author

Combining Stereotactic Radiotherapy and Conventional Radiotherapy for Peripheral Locally Advanced Lung Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2023

Radiotherapy can increase the risk of second primary cancers, especially in young patients. Optimizing radiation techniques is crucial to minimize this risk while effectively treating the initial tumor.

Area of Science:

  • Oncology
  • Radiation Oncology
  • Cancer Epidemiology

Background:

  • Prolonged survival after radiotherapy increases the incidence of second primary cancers.
  • Cumulative incidence of second primary malignancy after radiotherapy (SPMAR) can reach 20% within 40 years for patients treated at age 40.
  • A significant proportion of SPMAR may be directly promoted by irradiation.

Purpose of the Study:

  • To analyze the risk and characteristics of second primary malignancy after radiotherapy (SPMAR).
  • To highlight the elevated risk in younger patient populations.
  • To discuss the complexity of SPMAR quantification, mechanisms, and risk factors.

Main Methods:

  • Relative risk (RR) analysis to estimate the proportion of radiation-attributable second cancers.

Related Experiment Videos

Last Updated: Jun 11, 2026

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
10:48

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

  • Review of existing studies on SPMAR in adult and young patients.
  • Discussion of risk factors and biomolecular mechanisms.

    • Main Results:

    • Adult patients show a relative risk (RR) of approximately 1.1 for SPMAR.
    • Young patients exhibit a significantly higher RR of about 6 for SPMAR.
    • The quantification, mechanisms, and risk factors of SPMAR remain complex and not fully understood.

    Conclusions:

    • SPMAR is a significant concern in long-term cancer survivors treated with radiotherapy.
    • Younger patients face a substantially higher risk of radiation-induced second cancers.
    • Irradiation technique optimization is essential, particularly for young patients, to balance tumor dose with organ-at-risk sparing, though definitive standards are pending.